adult
frequent
develop
eustachian
tube
dysfunct
middl
ear
pressur
mep
abnorm
natur
experiment
influenza
human
rhinoviru
hrv
infect
oral
rimantadin
treatment
reduc
otolog
manifest
experiment
influenza
adult
natur
influenza
children
howev
intranas
zanamivir
oral
oseltamivir
significantli
reduc
mep
abnorm
experiment
influenza
adult
oseltamivir
treatment
appear
reduc
likelihood
otiti
media
children
acut
influenza
investig
antihrv
agent
includ
intranas
tremacamra
intranas
oral
pleconaril
warrant
studi
regard
depend
viru
earli
antivir
therapi
potenti
impact
risk
otiti
media
follow
respiratori
tract
infect
new
episod
otiti
media
tempor
associ
acut
viral
respiratori
tract
ill
vri
follow
vri
risk
develop
clinic
manifest
otiti
media
highli
age
relat
although
rel
common
respiratori
viral
infect
children
lead
otiti
media
effus
ome
acut
otiti
media
aom
frequenc
complic
much
lower
adolesc
adult
exampl
among
adult
teenag
mostli
previous
healthi
acut
influenza
viru
ill
develop
physician
diagnos
ear
infect
lead
antibiot
similarli
among
adult
proven
human
rhinoviru
hrv
ill
two
instanc
presum
aom
document
studi
involv
person
howev
adult
frequent
develop
eustachian
tube
et
dysfunct
middl
ear
pressur
mep
abnorm
natur
occur
experiment
induc
vri
tympanometr
measur
children
also
document
associ
upper
respiratori
tract
ill
otiti
media
measur
chang
provid
object
mean
assess
effect
therapeut
intervent
import
differ
may
exist
among
common
respiratori
virus
propens
caus
aom
infant
children
one
longitudin
day
care
studi
found
infect
influenza
b
respiratori
syncyti
viru
rsv
adenoviru
confer
greater
risk
otiti
media
infect
parainfluenza
viru
piv
enteroviru
human
rhinoviru
hrv
recent
pediatr
studi
virolog
evid
middl
ear
invas
rsv
piv
influenza
b
often
enteroviru
adenoviru
middl
ear
fluid
mef
sampl
obtain
tympanocentesi
pathogen
bacteria
recov
mef
contain
viru
often
associ
influenza
viru
howev
among
virus
respons
upper
respiratori
tract
infect
hrv
common
account
episod
anoth
recent
studi
children
age
month
year
aom
nasopharyng
aspir
mef
test
revers
transcriptionpolymeras
chain
reaction
rtpcr
viral
rna
hrv
rsv
human
coronaviru
hcv
threequart
children
detect
viral
rna
either
nasopharyng
aspir
sampl
andor
middl
ear
effus
one
three
common
respiratori
virus
hrv
rna
detect
mef
nasopharyng
aspir
mef
alon
nasopharyng
aspir
alon
aom
episod
link
hrv
infect
bacteri
pathogen
detect
mef
sampl
onehalf
hrvposit
mef
bacteri
pathogen
identifi
hrv
infect
also
link
higher
frequenc
antibiot
failur
mix
viral
bacteri
aom
respiratori
virus
well
develop
otiti
media
effus
ome
mechan
vri
caus
predispos
develop
aom
fulli
elucid
describ
presenc
viru
compon
antigen
nucleic
acid
mef
may
indic
replic
eustachian
tube
et
middl
ear
mucosa
potenti
direct
cytopath
effect
cytokin
elabor
inflammatori
respons
addit
direct
viral
invas
middl
ear
nasopharyng
inflamm
might
caus
et
dysfunct
due
secret
mucos
swell
impair
mucociliari
clearanc
andor
direct
mucos
damag
due
viru
could
reduc
clearanc
function
potenti
facilit
bacteri
infect
middl
ear
studi
experiment
induc
influenza
hrv
infect
adult
volunt
help
document
causal
relationship
vri
aom
use
object
measur
document
et
dysfunct
abnorm
middl
ear
pressur
mep
instanc
otiti
media
follow
infect
either
virus
tempor
sequenc
event
appear
initi
et
dysfunct
follow
alter
mep
regul
typic
lead
middl
ear
underpressur
underpressur
may
lead
aspir
nasopharyng
secret
middl
ear
prolong
accumul
fluid
develop
otiti
media
howev
rel
contribut
virusinduc
cytopatholog
host
inflamm
immunomodul
event
within
mucosa
upper
respiratori
tract
incomplet
defin
also
like
differ
among
differ
respiratori
virus
exampl
hrv
infect
caus
littl
histolog
detect
alter
upper
respiratori
mucosa
wherea
influenza
associ
substanti
epitheli
damag
measur
mep
chang
infect
imped
tympanometri
provid
use
tool
assess
object
sever
durat
pathophysiolog
abnorm
affect
middl
ear
exampl
comparison
otolog
outcom
adult
experiment
infect
influenza
hrv
type
found
frequenc
abnorm
mep
detect
tympanometri
increas
group
infect
hrv
infect
frequenc
reach
maximum
day
post
infect
time
subject
ear
affect
influenza
frequenc
abnorm
reach
maximum
day
post
infect
time
subject
ear
abnorm
abnorm
account
signific
underpressur
mmh
wherea
overpressur
mmh
occur
approxim
subject
physiolog
abnorm
tend
resolv
spontan
sever
day
frequenc
otoscop
evid
aom
rel
low
howev
experienc
otolaryngologist
found
otoscop
chang
approxim
hrvinfect
influenzainfect
volunt
case
asymptomat
although
influenzainfect
subject
develop
otalgia
uncommonli
purul
aom
although
two
viral
infect
differ
magnitud
nasal
secret
induc
infect
influenza
appear
provok
higher
frequenc
sever
mep
abnorm
otiti
media
may
reflect
increas
epitheli
damag
influenza
rel
rhinovirus
chang
mep
also
found
adult
natur
occur
influenza
hrv
ill
chang
evid
et
dysfunct
like
use
surrog
marker
risk
aom
develop
sinc
sustain
underpressur
associ
develop
mef
among
previous
healthi
adult
proven
febril
influenza
ill
major
mep
abnorm
mmh
primarili
underpressur
ill
abnorm
observ
b
observ
test
obtain
ill
adult
first
present
acut
influenza
gener
day
symptom
onset
abnorm
mep
valu
present
frequenc
increas
approxim
day
later
decreas
day
later
week
one
patient
sustain
underpressur
later
develop
overpressur
overt
aom
requir
antibiot
therapi
similarli
two
separ
studi
natur
hrv
infect
involv
total
adult
major
mep
abnorm
mmh
detect
subject
ill
underpressur
account
abnorm
measur
frequenc
abnorm
mep
valu
increas
first
day
approxim
day
remain
approxim
day
depend
studi
diminish
thereaft
clear
relationship
subject
complaint
ear
pain
cold
sever
found
studi
one
subject
bilater
underpressur
day
later
receiv
antibiot
appar
aom
studi
found
adult
proven
hrv
cold
residu
mep
abnorm
primarili
underpressur
week
rapid
spontan
resolut
chang
probabl
account
low
risk
aom
adult
natur
hrv
cold
avail
evid
suggest
otiti
media
develop
complic
viral
upper
respiratori
ill
due
disrupt
normal
et
function
turn
caus
middl
ear
underpressur
accumul
fluid
although
prevent
viral
infect
vaccin
reduc
risk
influenzaassoci
aom
remain
establish
whether
earli
inhibit
viral
replic
either
prevent
clinic
import
middl
ear
abnorm
develop
possibl
speed
resolut
establish
one
part
uncertainti
stem
lack
inform
import
ongo
viral
replic
caus
et
dysfunct
often
middl
ear
invad
viru
effect
prevent
middl
ear
complic
vri
may
requir
preemptiv
therapi
antivir
adjunct
antiinflammatori
agent
earli
treatment
viral
upper
respiratori
tract
ill
effect
antivir
might
prevent
develop
aom
decreas
viru
load
associ
pathophysiolog
abnorm
well
reduc
likelihood
direct
viral
invas
middl
ear
perhap
may
also
affect
bacteri
colon
likelihood
progress
purul
otiti
media
delay
develop
mep
chang
adult
hrv
particularli
influenza
suggest
opportun
interven
antivir
agent
reduc
likelihood
persist
mep
abnorm
eventu
aom
import
aspect
antivir
therapi
rout
administr
topic
administr
eg
nasal
drop
spray
unlik
deliv
effect
drug
concentr
et
middl
ear
oral
absorb
agent
distribut
respiratori
mucosa
much
like
inhibit
viral
replic
multipl
site
upper
respiratori
tract
experi
regard
antivir
therapi
hrv
infect
limit
remain
uncertain
whether
earli
treatment
might
prevent
middl
ear
diseas
pirodavir
capsidbind
antipicornavir
agent
vitro
activ
hrv
serotyp
seri
studi
experiment
hrv
infect
found
intranas
spray
given
viral
inocul
reduc
frequenc
viral
infect
clinic
cold
efficaci
wherea
day
administr
prophylaxi
earli
treatment
begin
h
viral
inocul
provid
clinic
benefit
correspond
reduct
frequenc
abnorm
mep
b
mmh
found
studi
employ
daili
prophylaxi
wherea
signific
differ
frequenc
abnorm
mep
found
three
trial
signific
clinic
effect
observ
find
indic
prevent
strategi
reduc
frequenc
hrv
cold
reduc
frequenc
associ
mep
abnorm
adult
natur
hrv
cold
durat
less
pirodavir
given
intranas
daili
awak
compar
placebo
among
person
laboratori
document
hrv
cold
pirodavir
treatment
associ
reduc
frequenc
viru
recoveri
day
treatment
signific
differ
resolut
respiratori
symptom
similarli
import
effect
observ
proport
patient
middl
ear
abnorm
treatment
period
major
abnorm
detect
placebo
pirodavir
recipi
enrol
proport
differ
significantli
group
day
placebo
vs
pirodavir
day
vs
day
vs
studi
one
pirodavir
recipi
treat
oral
antimicrob
otiti
media
begin
week
studi
entri
neg
find
predict
neg
observ
earli
treatment
experiment
cold
priodavir
describ
outcom
suggest
benefici
effect
mep
abnorm
requir
intervent
impact
degre
nasopharyng
inflamm
associ
symptom
anoth
small
studi
experiment
hrv
infect
test
efficaci
recombin
ifnb
given
earli
treatment
mu
daili
begin
h
infect
ill
rate
sever
differ
significantli
interferon
placebo
group
frequenc
viru
shed
reduc
sever
postchalleng
day
abnorm
et
function
least
one
ear
identifi
somewhat
less
often
observ
vs
observ
infect
interferon
recipi
compar
placebo
recipi
fraction
individu
detail
otolog
test
mep
abnorm
b
mmh
occur
least
one
ear
observ
interferon
recipi
compar
placebo
mark
underpressur
b
mmh
detect
three
five
placebo
compar
three
interferon
recipi
mark
underpressur
detect
observ
placebo
group
compar
interferon
group
result
suggest
interferon
administr
associ
earli
resolut
abnorm
et
function
mep
abnorm
perhap
antivir
immunomodul
effect
time
cours
resolut
et
mep
abnorm
interferon
group
parallel
viral
shed
observ
suggest
causal
relationship
viral
replic
near
et
may
caus
dysfunct
earli
antivir
treatment
abl
impact
process
valid
futur
studi
find
suggest
least
context
experiment
hrv
infect
possibl
interven
antivir
agent
shortli
infect
moder
middl
ear
abnorm
studi
need
determin
whether
earli
antivir
therapi
prevent
middl
ear
diseas
high
risk
group
recent
sever
investig
agent
differ
mechan
antivir
action
shown
antivir
clinic
activ
experimentallyinduc
hrv
coxsackieviru
suscept
adult
includ
intranas
administr
receptor
decoy
solubl
intracellular
adhes
tremacamra
oral
administr
antipicornaviru
capsidbind
pleconaril
intranas
administr
proteas
inhibitor
f
hayden
et
al
unpublish
observ
oral
pleconaril
appear
reduc
symptom
durat
sever
picornaviru
adult
warrant
studi
children
determin
possibl
effect
aom
develop
effect
antivir
intervent
cours
experiment
influenza
otolog
manifest
yield
somewhat
conflict
result
protein
inhibitor
rimantadin
test
studi
involv
suscept
adult
experiment
infect
influenza
viru
randomli
assign
oral
rimantadin
mg
placebo
twice
daili
day
begin
h
viral
inocul
initi
treatment
select
correspond
time
obviou
symptom
develop
rimantadin
treatment
associ
reduc
frequenc
viru
shed
day
challeng
lower
symptom
burden
trend
toward
reduc
ill
rate
rimantadin
vs
placebo
howev
rimantadin
effect
object
measur
nasal
patenc
mucociliari
clearanc
nasal
sign
specif
otolog
manifest
infect
frequenc
subject
develop
otalgia
overal
rimantadin
vs
placebo
peak
group
day
infect
decreas
similarli
proport
observ
abnorm
et
function
show
progress
increas
maximum
day
infect
diminish
thereaft
group
frequenc
abnorm
mep
increas
begin
day
treatment
initi
peak
day
later
differ
group
specif
number
day
abnorm
mep
b
mmh
treatment
similar
rimantadin
mean
day
placebo
day
group
three
episod
otiti
media
develop
rimantadin
group
compar
two
placebo
commonli
day
challeng
two
tympanocentesi
yield
mef
cultur
neg
viru
bacteria
children
age
year
acut
influenza
rimantadin
therapi
reduc
frequenc
viru
recoveri
ill
sever
first
sever
day
treatment
thereaft
frequenc
earach
otiti
higher
rimantadin
acetaminophen
recipi
studi
entri
import
treatment
affect
earach
frequenc
subsequ
found
day
rimantadin
vs
control
day
vs
result
suggest
rimantadin
therapi
either
prevent
develop
acceler
resolut
ear
complaint
potenc
time
antivir
intervent
import
variabl
regard
prevent
otolog
abnorm
inde
studi
antiinfluenza
neuraminidas
inhibitor
specif
intranas
zanamivir
oral
oseltamivir
given
earlier
time
point
cours
experiment
infect
found
benefici
effect
otolog
endpoint
surprisingli
prevent
influenza
ill
also
prevent
middl
ear
diseas
studi
experiment
influenza
infect
adult
prophylact
administr
intranas
zanamivir
start
viru
exposur
significantli
reduc
frequenc
infect
vs
uri
viral
titer
frequenc
ear
ach
pressur
vs
mep
abnorm
mmh
vs
importantli
earli
treatment
intranas
zanamivir
begin
h
viru
inocul
found
signific
reduct
frequenc
earach
vs
abnorm
mep
vs
among
infect
subject
well
reduct
number
day
mep
abnorm
gener
correl
presenc
overor
underpressur
presenc
ear
symptom
ear
ach
pressur
recogn
experiment
influenza
studi
howev
associ
recogn
prolong
underpressur
day
presenc
uri
symptom
day
furthermor
underpressur
correl
measur
viral
replic
observ
suggest
antivir
therapi
may
benefici
use
prophylaxi
experiment
influenza
viru
infect
oral
oseltamivir
twice
daili
also
highli
protect
viru
recoveri
upper
respiratori
tract
viru
associ
infectionrel
ill
earli
oseltamivir
treatment
begin
h
viral
inocul
also
associ
signific
antivir
effect
reduc
symptom
score
lower
nasal
proinflammatori
cytokin
level
tnfa
ifng
associ
halv
nasal
mucu
weight
symptom
score
reduct
durat
viral
shed
time
allevi
ill
frequenc
upper
respiratori
tract
ill
reduc
signific
mep
abnorm
seen
placebo
recipi
compar
receiv
oseltamivir
result
substanti
link
viru
replic
cytokin
elabor
symptom
product
acut
influenza
find
also
indic
earli
inhibit
viral
replic
regul
seri
respons
reduc
likelihood
signific
et
dysfunct
lead
abnorm
mep
howev
sign
symptom
experiment
infect
rel
mild
compar
natur
occur
influenza
patient
present
medic
care
time
antivir
intervent
earlier
despit
caveat
preliminari
analysi
result
studi
children
age
year
acut
influenza
found
oseltamivir
treatment
provid
symptom
benefit
reduc
likelihood
aom
develop
find
indic
earli
antivir
intervent
reduc
risk
middl
ear
diseas
influenza
children
